NCT00048230: Phase 3 - PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With RRMM
Phase 3 - PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma NCT00048230 This...
Dec 13, 2002
132
IFM 9502 trial: 200 mg/m(2) melphalan Vs 8 Gy TBI + 140 mg/m(2) melphalan as conditioning Blood 2002
(Intergroupe Francophone du Myélome [IFM] 9502 trial) Time Frame: July 1995 to January 1999 IFM 9502 trial: 200 mg/m(2) melphalan Vs 8...
Dec 8, 2002
30